BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for ABBVIE · Biopharmaceutical company

Filing 1st Quarter - Amendment

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · Senate · $80,000.00 income · posted Apr 18, 2025

Lobbying activity 1

Health Issues

Issues related to patient access, pharmaceutical manufacturing, Patent reform and drug pricing both domestic and international Issues related to Medicare drug pricing and reimbursement

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.